German Industry Is Winning Medtech Aids Quality Battle, If Slowly
The price versus quality standoff surrounding the supply of medtech aids and assistive-care products prescribed in the German primary- and ambulatory-care settings goes on. A ban on tenders, which can imbalance the market with large supplies of lower-quality imports, has soothed industry’s frustrations, but the battle is not over yet.
You may also be interested in...
Germany’s new draft health-care access law includes provisions to make the currently complicated, under-used and slow innovation "fast-tracking" tools more practical. Manufacturers of products that can address unmet needs should welcome the new TSVG law, currently in draft, says the national IVDs industry association. But it’s not all good news for industry.
Meaningful medtech advances that have the potential to revolutionize patient care cannot happen by eliminating risk entirely, but it’s a balance that European stakeholders are failing to achieve consistently. This is so in Germany too, says the BVMed industry association, with negative consequences for those at the sharp end of innovation – the SMEs and start-ups who originate a vast proportion of medtech advances.
Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”